{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:15:21Z","timestamp":1791155721241,"version":"4.1.0"},"reference-count":32,"publisher":"Spandidos Publications","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.3892\/ol.2016.5093","type":"journal-article","created":{"date-parts":[[2016,9,5]],"date-time":"2016-09-05T14:04:18Z","timestamp":1473084258000},"page":"3041-3044","source":"Crossref","is-referenced-by-count":13,"title":["Genetics and epigenetics of melanoma"],"prefix":"10.3892","volume":"12","author":[{"given":"Xiao-Ying","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2016,9,5]]},"reference":[{"key":"key20180108111242_b1-ol-0-0-5093","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2016.03.022","article-title":"Tumor associated B cells in cutaneous primary melanoma and improved clinical outcome","author":"Garg","year":"2016","journal-title":"Hum Pathol"},{"key":"key20180108111242_b2-ol-0-0-5093","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.annepidem.2004.10.005","article-title":"Cutaneous malignant melanoma in women. Phenotypic characteristics, sun exposure, and hormonal factors: A case-control study from Italy","volume":"15","author":"Naldi","year":"2005","journal-title":"Ann Epidemiol"},{"key":"key20180108111242_b3-ol-0-0-5093","doi-asserted-by":"crossref","first-page":"217.e5","DOI":"10.1016\/j.neurobiolaging.2016.02.026","article-title":"MC1R variants in Chinese Han patients with sporadic Parkinsons disease","volume":"42","author":"Shi","year":"2016","journal-title":"Neurobiol Aging"},{"key":"key20180108111242_b4-ol-0-0-5093","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/ijc.29018","article-title":"M-SKIP Study Group: MC1R variants increased the risk of sporadic cutaneous melanoma in darker-pigmented Caucasians: a pooled-analysis from the M-SKIP project","volume":"136","author":"Pasquali","year":"2015","journal-title":"Int J Cancer"},{"key":"key20180108111242_b5-ol-0-0-5093","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/pcmr.12333","article-title":"Genetics of familial melanoma: 20 years after CDKN2A","volume":"28","author":"Aoude","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"key20180108111242_b6-ol-0-0-5093","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/nrclinonc.2013.83","article-title":"Paradoxical oncogenesis - the long-term effects of BRAF inhibition in melanoma","volume":"10","author":"Gibney","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"key":"key20180108111242_b7-ol-0-0-5093","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/ng.950","article-title":"Exon capture analysis of G protein-coupled receptors identifies activating mutations in GRM3 in melanoma","volume":"43","author":"Prickett","year":"2011","journal-title":"Nat Genet"},{"key":"key20180108111242_b8-ol-0-0-5093","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/CMR.0000000000000121","article-title":"GNAQ and GNA11 mutations in uveal melanoma","volume":"24","author":"Shoushtari","year":"2014","journal-title":"Melanoma Res"},{"key":"key20180108111242_b9-ol-0-0-5093","first-page":"49","article-title":"Immune escape mechanisms in malignant melanoma","volume":"3","author":"Geertsen","year":"1999","journal-title":"Int J Mol Med"},{"key":"key20180108111242_b10-ol-0-0-5093","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00008390-199902000-00007","article-title":"The chemoresistance of human malignant melanoma: An update","volume":"9","author":"Serrone","year":"1999","journal-title":"Melanoma Res"},{"key":"key20180108111242_b11-ol-0-0-5093","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/jlb.62.5.588","article-title":"Mechanism and biological significance of constitutive expression of MGSA\/GRO chemokines in malignant melanoma tumor progression","volume":"62","author":"Luan","year":"1997","journal-title":"J Leukoc Biol"},{"key":"key20180108111242_b12-ol-0-0-5093","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/ng0994-15","article-title":"Germline p16 mutations in familial melanoma","volume":"8","author":"Hussussian","year":"1994","journal-title":"Nat Genet"},{"key":"key20180108111242_b13-ol-0-0-5093","doi-asserted-by":"crossref","first-page":"10968","DOI":"10.1073\/pnas.0611638104","article-title":"ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence","volume":"104","author":"Ha","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"key20180108111242_b14-ol-0-0-5093","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1038\/jid.2010.138","article-title":"Alterations in the p53 pathway and p16INK4a expression predict overall survival in metastatic melanoma patients treated with dacarbazine","volume":"130","author":"Busch","year":"2010","journal-title":"J Invest Dermatol"},{"key":"key20180108111242_b15-ol-0-0-5093","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/107327480901600302","article-title":"Epigenetics in human melanoma","volume":"16","author":"Howell","year":"2009","journal-title":"Cancer Control"},{"key":"key20180108111242_b16-ol-0-0-5093","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.tibs.2005.12.008","article-title":"Genomic DNA methylation: the mark and its mediators","volume":"31","author":"Klose","year":"2006","journal-title":"Trends Biochem Sci"},{"key":"key20180108111242_b17-ol-0-0-5093","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0002-9440(10)64174-0","article-title":"Significant impact of promoter hypermethylation and the 540 C>T polymorphism of CDKN2A in cutaneous melanoma of the vertical growth phase","volume":"161","author":"Straume","year":"2002","journal-title":"Am J Pathol"},{"key":"key20180108111242_b18-ol-0-0-5093","first-page":"1639","article-title":"Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma","volume":"63","author":"Spugnardi","year":"2003","journal-title":"Cancer Res"},{"key":"key20180108111242_b19-ol-0-0-5093","doi-asserted-by":"crossref","first-page":"6546","DOI":"10.1158\/0008-5472.CAN-06-0384","article-title":"Epigenetic silencing of the PTEN gene in melanoma","volume":"66","author":"Mirmohammadsadegh","year":"2006","journal-title":"Cancer Res"},{"key":"key20180108111242_b20-ol-0-0-5093","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/DAD.0b013e3182964e02","article-title":"Immunohistochemistry for histone h3 lysine 9 methyltransferase and demethylase proteins in human melanomas","volume":"36","author":"Miura","year":"2014","journal-title":"Am J Dermatopathol"},{"key":"key20180108111242_b21-ol-0-0-5093","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/pcmr.12280","article-title":"EZH2: an emerging role in melanoma biology and strategies for targeted therapy","volume":"28","author":"Tiffen","year":"2015","journal-title":"Pigment Cell Melanoma Res"},{"key":"key20180108111242_b22-ol-0-0-5093","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1038\/onc.2012.307","article-title":"MicroRNA miR-125b controls melanoma progression by direct regulation of c-Jun protein expression","volume":"32","author":"Kappelmann","year":"2013","journal-title":"Oncogene"},{"key":"key20180108111242_b23-ol-0-0-5093","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.1007\/s13277-015-4409-8","article-title":"MicroRNA-125b suppresses the epithelial-mesenchymal transition and cell invasion by targeting ITGA9 in melanoma","volume":"37","author":"Zhang","year":"2016","journal-title":"Tumour Biol"},{"key":"key20180108111242_b24-ol-0-0-5093","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3322\/canjclin.50.4.215","article-title":"Malignant melanoma: Prevention, early detection, and treatment in the 21st century","volume":"50","author":"Rigel","year":"2000","journal-title":"CA Cancer J Clin"},{"key":"key20180108111242_b25-ol-0-0-5093","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1200\/JCO.2013.50.1114","article-title":"Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma","volume":"31","author":"Han","year":"2013","journal-title":"J Clin Oncol"},{"key":"key20180108111242_b26-ol-0-0-5093","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.hoc.2014.02.006","article-title":"Treatments for noncutaneous melanoma","volume":"28","author":"Khalil","year":"2014","journal-title":"Hematol Oncol Clin North Am"},{"key":"key20180108111242_b27-ol-0-0-5093","doi-asserted-by":"crossref","first-page":"516","DOI":"10.3892\/ijo.2014.2481","article-title":"Emerging targeted therapies for melanoma treatment (review)","volume":"45","author":"Russo","year":"2014","journal-title":"Int J Oncol"},{"key":"key20180108111242_b28-ol-0-0-5093","first-page":"1481","article-title":"Melanoma: molecular pathogenesis and emerging target therapies (Review)","volume":"34","author":"Russo","year":"2009","journal-title":"Int J Oncol"},{"key":"key20180108111242_b29-ol-0-0-5093","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1634\/theoncologist.2010-0190","article-title":"Systematic review of medical treatment in melanoma: current status and future prospects","volume":"16","author":"Garbe","year":"2011","journal-title":"Oncologist"},{"key":"key20180108111242_b30-ol-0-0-5093","doi-asserted-by":"crossref","first-page":"e3406","DOI":"10.1097\/MD.0000000000003406","article-title":"Meta-analysis of the safety and efficacy of interferon combined with dacarbazine versus dacarbazine alone in cutaneous malignant melanoma","volume":"95","author":"Xin","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"key20180108111242_b31-ol-0-0-5093","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s00018-014-1791-0","article-title":"MITF in melanoma: Mechanisms behind its expression and activity","volume":"72","author":"Hartman","year":"2015","journal-title":"Cell Mol Life Sci"},{"key":"key20180108111242_b32-ol-0-0-5093","doi-asserted-by":"crossref","first-page":"352","DOI":"10.3389\/fonc.2014.00352","article-title":"Melanoma cells revive an embryonic transcriptional network to dictate phenotypic heterogeneity","volume":"4","author":"Vandamme","year":"2014","journal-title":"Front Oncol"}],"updated-by":[{"DOI":"10.3892\/ol.2020.12045","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"record-id":"24113"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ol.2016.5093\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T06:21:29Z","timestamp":1718778089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2016.5093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,5]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,9,5]]},"published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.3892\/ol.2016.5093"],"URL":"https:\/\/doi.org\/10.3892\/ol.2016.5093","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,5]]}}}